Kalaris Therapeutics Stock (NASDAQ:KLRS)


OwnershipChart

Previous Close

$7.57

52W Range

$2.14 - $12.90

50D Avg

$5.61

200D Avg

$5.02

Market Cap

$157.29M

Avg Vol (3M)

$175.85K

Beta

-0.05

Div Yield

-

KLRS Company Profile


Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

14

IPO Date

Jul 30, 2020

Website

KLRS Performance


Latest Earnings Call Transcripts


Q4 12Mar 04, 13 | 5:00 PM
Q3 12Nov 14, 12 | 5:00 PM
Q2 12Aug 02, 12 | 5:00 PM

Peer Comparison


TickerCompany
IMAImageneBio Inc
QNCXQuince Therapeutics, Inc.
ARTVArtiva Biotherapeutics, Inc.
MGXMetagenomi, Inc. Common Stock
IFRXInflaRx N.V.
STROSutro Biopharma, Inc.
CNTXContext Therapeutics Inc.
OVIDOvid Therapeutics Inc.
CNTBConnect Biopharma Holdings Limited
STTKShattuck Labs, Inc.